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BRIEF DEFINITIVE REPORT
        The cyclooxygenase (COX) pathway in vascu-
lar endothelium plays important roles in throm-
bosis, atherosclerosis, and vascular infl  ammation 
(  1  ). Vascular endothelial cells (ECs) constitu-
tively express COX-1 and -2 isoenzymes, lead-
ing to the generation of prostacyclin (PGI  2 ) and 
related molecules (  2  ). PGI  2 , a well-known in-
hibitor of platelet aggregation and a vasodilator, 
activates the IP-subtype of G protein  –  coupled 
receptors on the plasma membrane of platelets 
and vascular smooth muscle cells (  1, 3  ). In addi-
tion to activating cell surface receptors, PGI  2  
and related molecules are potent activators of 
nuclear peroxisomal proliferator  –  activated re-
ceptor (PPAR)       (  4  –  6  ). This mechanism was 
shown to be important for embryo implantation 
in mice (  6  ) and in intestinal adenoma cell prolif-
eration (  7  ) and angiogenesis (  8  ). 
  The role of COX-2 in the regulation of 
EC phenotype is not well understood. In small-
vessel endothelium, COX-2 is induced by growth 
factors and cytokines during infl  ammation and 
angiogenesis (  9  ). In large-vessel ECs, COX-2 is 
constitutively expressed as a laminar shear  –  in-
ducible gene (  10  ), which may be important for 
normal vascular homeostasis (  11  ). This issue has 
recently received considerable attention because 
administration of COX-2  –  specifi  c inhibitors 
(also known as the coxibs) leads to a small but 
substantial increase in prothrombotic side eff  ects 
in humans, leading to the withdrawal of rofe-
coxib and valdecoxib from the market (  12, 13  ). 
The mechanistic basis of these side eff  ects is not 
clearly understood, even though PGI  2 -dependent 
platelet eff  ects and thromboxane-  dependent vas-
cular pathology have been implicated (  14, 15  ). 
In this study, we show that metabolism of 
endocannabinoids by the COX-2 pathway re-
sults in direct activation of the nuclear receptor 
PPAR     . We further show that this pathway 
suppresses the expression of tissue factor (TF), 
which is a primary regulator of blood coagulation. 
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  Although cyclooxygenase (COX)-2 inhibitors (coxibs) are effective in controlling infl  amma-
tion, pain, and tumorigenesis, their use is limited by the recent revelation of increased 
adverse cardiovascular events. The mechanistic basis of this side effect is not well under-
stood. We show that the metabolism of endocannabinoids by the endothelial cell COX-2 
coupled to the prostacyclin (PGI  2 ) synthase (PGIS) activates the nuclear receptor peroxi-
somal proliferator  –  activated receptor (PPAR)     , which negatively regulates the expression 
of tissue factor (TF), the primary initiator of blood coagulation. Coxibs suppress PPAR     
activity and induce TF expression in vascular endothelium and elevate circulating TF activ-
ity in vivo. Importantly, PPAR     agonists suppress coxib-induced TF expression and decrease 
circulating TF activity. We provide evidence that COX-2  –  dependent attenuation of TF 
expression is abrogated by coxibs, which may explain the prothrombotic side-effects for 
this class of drugs. Furthermore, PPAR     agonists may be used therapeutically to suppress 
coxib-induced cardiovascular side effects. 2054 COX-2/PPAR  PATHWAY REGULATES TF EXPRESSION | Ghosh et al.
(  Fig. 1 B  ). In addition, a dominant-negative PPAR      construct 
(  7  ) blocked the endocannabinoid-induced reporter activation 
(unpublished data). 
  Endocannabinoids are known to activate their G protein  –
  coupled receptors CB1 and CB2 (  18  ). To determine whether 
the observed eff  ects of endocannabinoids are mediated by 
CB receptors, we derived lung ECs from   CB1/CB2   double 
knockout mice (Fig. S1, available at http://www.jem.org/cgi/ 
content/full/jem.20070828/DC1) (  19  ). We found that 2-AG 
stimulated PPAR-dependent transcription in these cells lacking 
both CB1 and CB2 to an equivalent level of wild-type cells, 
suggesting that endocannabinoids are not acting via CB recep-
tors (  Fig. 1 C  ). In contrast, when the   PPAR       -null lung ECs 
(  20  ) were used in a similar assay, 2-AG failed to induce tran-
scriptional activation, suggesting an absolute requirement for 
this transcription factor. 
  We next tested if COX-2 enzyme activity is required for 
2-AG  –  induced PPAR      transcription. Indeed, 2-AG  –  induced 
PPAR      transcription in ECs was completely inhibited by 
NS-398, a COX-2  –  selective inhibitor, but not by valeryl 
  salicylate (VSA), a COX-1  –  specifi  c inhibitor (  Fig. 2 A  ).   How-
ever, NS398 or VSA alone did not have any eff  ect on PPAR       − 
dependent transcription. 2-AG  –  induced PPAR transcription 
was absent in HCT116 colon cancer cells, which lack COX-2 
expression but express COX-1 endogenously (  Fig. 2 B  ) (  21  ). 
In contrast, direct activation of PPAR      by cPGI, which is a 
stable PGI  2  analogue, induced transcription in HCT116 cells. 
More importantly, overexpression of COX-2 by adenoviral-
mediated transduction into HUVECs strongly induced PPAR     
transcription (    25-fold), and this response was further poten-
tiated (    40-fold) by 2-AG (  Fig. 2 C  ). This increase was blocked 
by NS-398. Although COX-2 expression with the adenovirus 
induced high basal activity of the PPAR-responsive reporter, 
this is probably caused by effi   cient transduction ( 90% for 
HUVECs) and accumulation of COX-2 enzyme during the 
This description of the antithrombotic function of COX-2 may 
contribute to the mechanistic understanding of coxib-induced 
cardiovascular side eff  ects seen in humans. 
    RESULTS AND DISCUSSION   
  The COX-2 isoenzyme has a larger active site pocket than 
COX-1 and therefore is capable of oxidizing many polyunsat-
urated fatty acids in addition to the common substrate arachi-
donic acid (AA) (  16  ). We tested if metabolism of various 
substrates of COX-2 would lead to intracellular activation of 
PPAR      in ECs. Human umbilical vein ECs (HUVECs), which 
express COX-2 were transfected with a PPAR-responsive 
transcription reporter (pACO-Luc) (  17  ), incubated with vari-
ous fatty acid substrates and transcriptional reporter (luciferase) 
activity was measured. As shown in   Fig. 1 A  , endocannabi-
noids, 2-arachidonyl glycerol (2-AG), noladin ether (NE), and 
anandamide (AEA) stimulated PPAR-dependent transcription.   
In contrast, the eff  ect of AA was modest, and neither n-3 fatty 
acids (docosahexaenoic acid or eicosapentaenoic acid) nor 
non  –  COX-2 substrates (palmitate or oleate) induced PPAR-
dependent transcription. The concentration of endocannabi-
noids that induced transcription is signifi  cantly below the K  m   of 
2-AG for COX-2, which is estimated to be     4      M (  16  ). NE, 
which is a nonhydrolyzable ether analogue of 2-AG, is more 
potent, suggesting that hydrolytic pathways are involved in at-
tenuating the 2-AG eff  ect. These data provide evidence that 
endocannabinoid ligands, which are alternative substrates for 
COX-2 but not COX-1, are capable of activating the endoge-
nous PPAR system in ECs. 
  The Gal4-UAS  –  based transcription reporter system was 
used to distinguish between the three PPAR isoforms (  7  ), all 
of which are expressed in vascular ECs (  17  ). We observed 
that 2-AG primarily induces PPAR       −  dependent transcrip-
tional activation in a dose-dependent manner, without signifi  -
cantly infl  uencing PPAR     - or PPAR    -dependent transcription 
  Figure 1.     Endocannabinoids induce PPAR    -dependent transcription in HUVECs. (A) HUVECs were transiently transfected with PPRE-luciferase 
reporter plasmid pACO-gLuc, and after 24 h cells were incubated with vehicle (DMSO), fatty acids (AA, DHA, and OA), or endocannabinoids (2G, AEA, and NE). 
Subsequently, luciferase activity was measured as described in Materials and methods. (*, P   0.05; **, P   0.01 compared with AA). Structures of the 
endocannabinoids are shown in Fig. S4. (B) Endocannabinoid activation of endogenous PPAR     -dependent transcription. A chimeric receptor containing 
the ligand-binding domain of PPAR    ,   ,     fused with the DNA-binding domain of yeast Gal4 transcription factor was used. Transactivation was detected 
by cotransfection with reporter gene (Gal4 response element [UAS-tk-luc]) in the presence of 2-AG (*, P   0.05; **, P   0.01, compared with vehicle). 
(C) Mouse lung ECs were isolated from wild-type (yellow),   PPAR     /     (green), or   CB1   /  /CB2  /     (blue) mice, and the Gal4-UAS system of transcriptional 
activation was assayed in the presence of vehicle (DMSO), 1 or 10      M 2-AG, or 10     M  PPAR     agonist cPGI as control (*, P   0.05; **, P   0.01 compared 
with vehicle). Fig. S4 is available at http://www.jem.org/cgi/content/full/jem.20070828/DC1.     JEM VOL. 204, September 3, 2007  2055
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time course of the adenoviral expression. Similar arguments 
likely explain the incomplete inhibition by COX-2 inhibitor. 
Together, these results (overexpression, inhibitor sensitivity, 
and COX-2  –  null cell data) establish that COX-2 activity is 
required for 2-AG  –  induced PPAR      transcription. 
  Once fatty acid substrates are metabolized by COX-2 into 
endoperoxides, terminal synthases catalyze the formation of 
active prostanoids (  1  ). To determine which of the prostanoids 
are involved in PPAR      transcription, we silenced the expres-
sion of genes encoding prostanoid synthases by siRNA in 
HUVECs and assayed the 2-AG  –  stimulated transcriptional re-
sponse. As shown in   Fig. 3 A  , quantitative (q) RT-PCR anal-
ysis indicates that PGF  2       synthase (PGFS) and PGI  2   synthase 
(PGIS) mRNAs are highly expressed in HUVECs, although 
lower levels of cytosolic PGE  2   synthase mRNA are also 
expressed.   The inducible microsomal PGE  2   synthase mRNA 
was not detected under basal conditions. This is consistent 
with our previous observation of abundant synthesis of 6-keto-
PGF  1       (a stable breakdown product of PGI  2  ), PGF  2      , and 
PGE  2   in HUVECs (  22  ). PGIS or PGFS siRNA signifi  -
cantly suppressed the expression of PGIS or PGFS mRNAs 
in HUVECs, respectively (  Fig. 3 B  ). As shown in   Fig. 3 C,   
2-AG  –  induced PPAR     transcription was inhibited by the PGIS, 
but not by the PGFS siRNA. These data suggest that conver-
sion of 2-AG by COX-2 and PGIS into PGI  2   glycerol ester is 
critical for PPAR      activation in ECs. Attempts to purify the 
PGI  2   glycerol ester or 6-keto-PGF  1       glycerol ester from EC 
extracts were not successful, which is presumably caused by 
high hydrolytic conversion of prostaglandin glycerol esters by 
cytosolic esterases (  23  ). 
  Because of the prothrombotic eff  ects of coxibs observed in 
some patients (  15, 24  ), we analyzed the eff  ect of modulating 
the COX-2  –  PPAR      pathway on TF expression in ECs. TF is 
the primary cellular initiator of blood coagulation, and its ex-
pression within the vasculature is associated with thrombosis 
(  25  ). We found that the COX-2 inhibitors celecoxib and 
NS398 induced TF mRNA expression, as determined by 
qRT-PCR (  Fig. 4 A  ).   In contrast, activation of the COX-2  –
  PPAR      pathway with either 2-AG or GW501516 decreased 
basal TF mRNA expression (  Fig. 4 A  ). Furthermore, 2-AG 
reduced celecoxib induction of TF mRNA expression (  Fig. 
4 A  ). These data suggest that inhibition of COX-2 induces 
TF expression, whereas activation of the COX-2  –  PPAR      
pathway suppresses TF expression. We isolated lung ECs from 
  Figure 2.     COX  –  2 activity is required for endocannabinoid-induced 
PPAR     transcription. (A) HUVECs were transiently transfected with 
pACO-gLuc as described in Fig. 1. Cells were pretreated with a COX-2  –
  selective inhibitor (NS398; 10      M) or a COX-1  –  selective inhibitor 
(VSA; 500      M) for 30 min, followed by the addition of 2-AG or DMSO 
(vehicle) for 16 h (*, P       0.05, compared with vehicle). (B) Transactivation 
of the PPRE reporter plasmid in HUVECs (blue), but not in HCT116 (gray), 
which is a COX-2  –  null cell line. (B, insets) mRNA levels of COX-1 and -2 
in these cells by qRT-PCR (*, P       0.05; **, P       0.01, compared with vehicle). 
(C) Over  expression of COX-2 enhances 2-AG  –  induced PPAR      transactivation. 
HUVECs were transduced with either adeno-GFP (green) or adeno  –  COX-2 
virus (blue) treated with 1      M 2-AG as in Fig. 1, with or without 10     M 
NS-398, and PPAR      transcriptional activity was assayed as in Fig. 1. (C, inset) 
COX-2 mRNA expression (**, P       0.01, compared with control vector virus, 
inset *, P       0.05; compared with vehicle).     
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activation maintains the antithrombotic phenotype of the nor-
mal endothelium by suppressing the TF gene. 
  When HUVECs were treated with LPS, large induction of 
TF mRNA was seen; however, PPAR      expression was not 
  altered (  Fig. 4 B   and not depicted). In fact, TF mRNA can be 
detected by Northern blot only after LPS treatment. COX-2 
inhibitors NS398 and celecoxib enhanced LPS induction of 
TF mRNA expression (  Fig. 4 B  ). Similarly, celecoxib enhanced 
LPS induction of TF protein expression (  Fig. 4 C  ). In contrast, 
the PPAR      agonist GW501516 and 2-AG both decreased LPS 
induction of TF mRNA expression (  Fig. 4 B  ). Concomitant 
regulation of TF polypeptide expression was observed as deter-
mined by an immunoblot assay (  Fig. 4 C  ). Rofecoxib, another 
COX-2  –  selective inhibitor, also enhanced LPS induction of 
PPAR     /  mice and tested the expression of TF by qRT-
PCR (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20070828/DC1). Unexpectedly, TF expression was 
lower than the wild-type counterparts. This phenomenon is 
analogous to the regulation of infl  ammatory gene expression 
by PPAR      in macrophages (  26  ). These authors showed that 
although PPAR      agonists suppressed infl  ammatory genes, 
PPAR     -null macrophages had low expression of such genes. 
They further showed that release of the transcriptional repres-
sor Bcl6 from the apo-PPAR      is responsible for suppression of 
infl  ammatory gene expression. We believe that an analogous 
phenomenon is operative in our   PPAR      -null ECs. Although 
molecular details of such mechanisms need to be further 
elucidated, our data suggest that COX-2  –  dependent PPAR      
  Figure 3.     Role of PG synthases in endocannabinoid-induced PPAR     transactivation. (A) Expression profi  le of PG synthases in HUVECs was deter-
mined by real-time PCR. Expression level (Ro) for each gene was normalized to glyceraldehyde-3-phosphate dehydrogenase. (B) Expression of PGIS or 
PGFS mRNA in HUVECs after treatment with 100 nM of PGFS or PGIS siRNA (*, P   0.05, compared with control siRNA). (C) Effects of silencing PGFS or 
PGIS on PPAR      transactivation in response to 2-AG. Cells were transfected with PGFS or PGIS siRNA with Oligofectamine for 4 h, and were allowed to 
recover in complete growth medium. After 16 h, cells were transiently transfected with PPAR     -GAL4, UAS-tk-luc, and p     -gal with Lipofectamine in 
OptiMEM, followed by addition of 2-AG. Cells were harvested for luciferase activity after 24 h (*, P   0.05, compared with vehicle).     
  Figure 4.     COX-2 inhibitors enhance, whereas PPAR     activators suppress, TF gene expression in ECs. (A) qRT-PCR analysis of total RNA extracted 
from HUVECs upon treatment with 10  M celecoxib, 10  M NS398, 10  M GW501516, 10  M 2-AG, or DMSO (vehicle) for 3 h. Celecoxib and NS-398 
were added 30 min before stimulation with 2-AG or GW501516 for 6 h. Human TF mRNA levels were normalized by the internal control gene GAPDH (*, P   
0.05; **, P  0.01, compared with vehicle). (B) Northern blot analysis of HUVECs treated with LPS for 3  –  6 h in the presence or absence of COX-2 inhibitors, 
GW501516, or 2-AG, as described in A. (C) Western blot analysis of TF expression in HUVECs. (D) TF expression in HUVEC extracts was assayed by Western 
blot analysis as described in Materials and methods. Cells were treated with indicated concentrations (micromolar) of various compounds (D and E) in the 
presence of 10  g/ml LPS. (E) TF activity assay in LPS-stimulated HUVEC lysates treated as outlined above. TF concentration of test samples was directly 
calculated from the standard curve. *, P   0.05; **, P   0.01, compared with vehicle.     JEM VOL. 204, September 3, 2007  2057
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by the EC COX-2  –  PGIS system has important intracellular 
signaling fates. It is known that 2-AG is released upon cellular 
activation of platelets, monocytes, and ECs (  30, 31  ). Recent 
work shows that metabolism of 2-AG by the COX-2 path-
way of the vascular endothelium occurs under physiological 
conditions and limits the activation of the CB receptors (  32  ). 
Although regulation of 2-AG production in human ECs need 
to be further examined, our data support the notion that 2-
AG metabolism by the EC COX-2 pathway is biologically 
important. We speculate that the glycerol moiety of 2-AG 
may hinder its rapid secretion into the extracellular milieu, 
thereby facilitating the activation of intracellular receptors. 
Second, basal expression of COX-2 by EC, which is generally 
thought to be caused by physiological pulsatile shear forces 
(  10  ), may be important for the tonic production of PPAR      
activators by the PGIS pathway. Our data supports the notion 
that 2-AG is an endogenous mediator that regulates the 
thrombotic phenotype of the vascular endothelium. Thus, 
  antagonism of this pathway by COX-2 inhibitors would be 
anticipated to disrupt this endogenous regulatory mechanism 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20070828/DC1). In this context, recent work shows that 
15-epi-lipoxin A  4  , which is an endogenous antiinfl  ammatory 
mediator derived from EC COX-2 is also inhibited by the 
coxib treatment (  33  ), suggesting that multiple lipid mediators 
are perturbed by these drugs. 
  Third, we suggest that the PPAR      pathway attenuates 
prothrombotic TF gene expression, and thus keeps the endo-
thelium in an antithrombotic state. Recent work has high-
lighted the prothrombotic side eff  ects of COX-2 inhibitors 
(coxibs) in humans (  34  ). Although the critical mechanisms 
involved remain to be elucidated, the importance of coxib 
inhibition of PGI  2 , the major vasoprotective prostanoid has 
been assumed to be the primary culprit (  2, 11, 14  ). Indeed, 
studies in mice show that perturbation of the PGI  2  receptor 
may control infl  ammatory vascular pathology (  11,14  ). Our 
study provides an alternative mechanism in understanding 
the prothrombotic complications of COX-2 inhibitors. Ele-
vated TF expression in the luminal surface of blood vessel and/
or plasma may be one of the factors that contribute to the 
development of cardiovascular events in patients consuming 
COX-2 inhibitors (  35  ). Recent reports show that the use of 
coxibs and nonsteroidal antiinfl  ammatory drugs are   associated 
with increased mortality risk in patients with a history of 
cardiovascular disease (  36, 37  ). It is important to note that 
the side eff  ects of coxibs only occur in a subset of patients, 
which is consistent with our in vitro data showing that coxibs 
induce TF expression modestly compared with LPS. Iden-
tifi  cation of the at-risk population would off  er obvious 
  advantages, as coxibs and nonsteroidal antiinfl  ammatory drugs 
are some of the most widely consumed antiinfl  ammatory 
drugs and have shown activity as anticancer and antiangiogenic 
agents. This study has provided a potential mechanism by 
which COX-2 inhibitors may contribute to thrombotic com-
plications, whereas a PPAR      agonist would likely alleviate 
such adverse events. 
TF protein expression in HUVECs in a dose-dependent 
manner, similar to celecoxib (  Fig. 4 D  ). 
  Next, we measured TF activity in HUVECs under simi-
lar experimental conditions. LPS induction of TF activity in 
HUVECs was enhanced by celecoxib in a dose-dependent 
manner (  Fig. 4 E  ). Preincubation of the cells with either 
GW501516 or 2-AG blocked this eff  ect, and these agents de-
creased LPS induction of TF activity (  Fig. 4 E  ). In contrast to 
the results with HUVECs, celecoxib did not induce TF activ-
ity in peripheral blood mononuclear cells and did not enhance 
LPS induction of TF activity (unpublished data), which may be 
caused by the diff  erences in the COX-2  –  PGIS  –  PPAR      path-
way in these cells. These fi  ndings indicate that the COX-2  –
  PPAR      pathway serves to attenuate LPS-induced TF expression 
in the vascular endothelium. In addition, our data show that 
inhibition of this pathway by COX-2 inhibitors leads to the 
induction of TF expression. 
  Our results are in apparent contradiction with a recent 
study that showed that celecoxib, but not rofecoxib, inhibited 
the induction of TF expression in human aortic ECs stimulated 
with TNF-      in vitro (  27  ). The authors of that paper suggested 
that inhibition of JNK activity is critical for the modulation of 
TF expression. There could be several reasons for these dis-
crepancies, e.g., diff  erences in signaling by diff  erent infl  amma-
tory stimuli (LPS vs. TNF-    ) in cell-specifi  c manner. However, 
in our work, we clearly show that the conversion of endocan-
nabinoid (2-AG) by the COX-2  –  PGIS pathway, followed by 
activation of PPAR     , is involved in the regulation of TF 
mRNA and protein expression, as well as activity in HUVECs. 
In addition, as shown in the following paragraph, both COX-2  –   
and PPAR     -dependent regulation of TF occurs in vivo as well. 
  We next determined whether the COX-2  –  PPAR      path-
way regulates TF expression in ECs in vivo. Immunohisto-
chemical analysis showed that LPS and/or celecoxib induced 
TF expression in ECs of blood vessels of lung and heart (  Fig. 
5 A  ).   Modulation of TF expression is seen in both microvessels 
and large vessels. GW501516 abolished this eff  ect (  Fig. 5 A  ). 
The observation is consistent with other reports showing that 
TF is expressed in the endothelium in other diseases associated 
with thrombosis (  28  ). 
  Activated ECs release TF-positive microparticles into plasma 
(  29  ). Therefore, we obtained platelet poor plasma (PPP) from 
mice orally administered with either celecoxib or GW501516, 
followed by intraperitoneal LPS administration. We observed 
that treatment of mice with either LPS or celecoxib increased 
plasma TF activity (Fig. 5 B). Treatment of mice with both 
LPS and celecoxib produced the highest levels of plasma TF, 
and such increase was abolished by pretreatment with the 
PPAR      activator GW501516 (Fig. 5 B). These data strongly 
suggest that the COX-2 pathway attenuates TF expression in 
vivo via the PPAR      pathway. Inhibition of COX-2 activity 
by coxibs results in the induction of TF expression in the 
endothelium, which is further enhanced under infl  amma-
tory conditions. 
  In summary, our results show the following novel fi  nd-
ings. First, metabolism of endocannabinoids, particularly 2-AG, 2058 COX-2/PPAR  PATHWAY REGULATES TF EXPRESSION | Ghosh et al.
(multiplicity of infection, 500), and the level of COX-2 expression was mea-
sured by either Western blot analysis or qRT-PCR. For transactivation assays 
after transfection, cells were transduced with either vector virus or adeno  –
  COX-2 virus for 16  –  24 h. Upon addition of COX-2 substrate, cells were 
harvested for luciferase activity as indicated above. Unless specifi  ed, all com-
pounds (2-AG, AA, GW501516, NS398, NE, AEA, and cPGI) were pur-
chased from Cayman Chemical. 
  qRT-PCR.     Total RNA was prepared using the RNA STAT-60 (Tel-test, 
Inc.) single-step isolation procedure according to the instructions provided by 
the manufacturer. 1      g total RNA was treated with DNase I before reverse 
transcription to ensure removal of all contaminating DNA. Using SYBR 
Green I DNA-binding dye technology (QIAGEN) reactions for each sample 
were done using an ABI 7900HT instrument (Applied Biosystems). All re-
actions underwent a fi  nal dissociation curve determination to ensure a single 
PCR product at the correct melting temperature. Fluorescence data were 
  exported and quantitated using a statistical model that corrects for PCR effi   -
ciency for each reaction. Results were expressed relative to the internal control 
gene glyceraldehyde-3-phosphate dehydrogenase for human or hypoxanthine 
phosphoribosyl-transferase I (HPRT) for mouse. Sequence of PCR primers 
were either obtained from the PrimerBank database (http://pga.mgh.harvard
    MATERIALS AND METHODS   
  Cell culture, transfection, transduction, and luciferase assays.     HUVECs 
(p3  –  6; Glyco Tech Corporation or VEC TECHNOLOGIES, Inc.) were cul-
tured as previously described (  38  ) in complete growth medium (M199, 10% 
FBS, growth factor, and 1% antibiotic-antimicotic agent). Human colon carci-
noma cells (HCT-116) were obtained from the American Type Culture Col-
lection and were grown in Dulbecco  ’  s modifi  ed Eagle  ’  s medium or RPMI 
with 10% FBS and 1% antibiotic-antimicotic agent. 
  For transient transfection, HUVECs (7.5       10  4   cells) were seeded in 
6-well plates, followed by transfection with a PPAR-responsive transcription 
reporter plasmid (pACO-gLUC),      -galactosidase plasmid (p-     gal), and Lipo-
fectamine 2000 in OPTI-MEM (Invitrogen) for 4 h, followed by the addition 
of 10% FBS containing media. After 16  –  24 h, 0.01  –  0.05% vehicle (DMSO) 
or indicated compounds were added and cells were harvested after 24 h in 1      
luciferase lysis buff  er. Relative light intensity from fi  refl  y luciferase activity 
was determined by using a luciferase kit (Promega) and a luminometer 
(Turner Designs). Relative luciferase activity was normalized to      -galactosi-
dase activity and protein content. All PPAR constructs were gifts from 
R. DuBois (Vanderbilt University Medical Center, Nashville, TN). 
  For adenoviral transduction, cells were infected with adenoviral vec-
tor containing human COX-2 cDNA or GFP cDNA as control for 48 h 
  Figure 5.     Regulation of TF expression in vivo by celecoxib and a PPAR     activator. C57BL/6J mice were treated with either vehicle (0.5% carboxy-
methyl cellulose), 25 mg/kg celecoxib, or 10 mg/kg GW501516 by gavage for 2 d. LPS (  E. coli   serotype 0111; B4; Sigma-Aldrich) was injected i.p. (100     g/ 
mouse). After 4  –  6 h, whole blood was collected from caudal vena cava into 10      acid citrate dextrose buffer to determine TF activity as previously described 
(see Materials and methods). Murine tissues were also harvested for immunohistochemistry. (A) Expression of TF protein in frozen tissue sections of lung and 
heart. Immunohistochemistry was conducted with monoclonal rat anti  –  mouse TF antibody and representative images are shown. The arrows and arrow-
heads indicate expression of TF protein in large vessels, as well as microvessels of both heart and lung. Bar, 20  m. (B) TF activity was measured in PPP as 
described in Materials and methods. TF concentration was interpolated as      A405-490 from a standard curve.   n   = 10 mice/group. *, P   0.05; **, P   0.01.     JEM VOL. 204, September 3, 2007  2059
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  Western blot analysis.     HUVECs were treated with indicated compounds, 
as described in Northern blot analysis. Cells were washed with ice-cold 
phosphate-buff  ered saline and harvested in radioimmunoprecipitation assay 
buff  er (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% SDS, 1% Triton X-
100, 0.25% sodium deoxycholate, 1% Nonidet P-40, 1 mM EDTA, 1 mM 
EGTA, and 1  ×   protease inhibitor cocktail). Cells were lysed by three cycles 
of freeze (dry-ice/ethanol bath) and thaw (20  °  C), followed by centrifugation 
at 14,000 rpm for 20 min. Protein concentrations of supernatants were de-
termined by BCA Protein Assay kit (Pierce Chemical Co.). Equal amounts 
of protein were separated on a 9% polyacrylamide gel and blotted to a nitro-
cellulose membrane for 1.5 h at 100 V. Immunoblot analysis was performed 
using 0.5      g/ml goat anti  –  human TF antibody (a gift from W. Ruf, The 
Scripps Research Institute, La Jolla, CA) and detected by horseradish peroxi-
dase  –  conjugated rabbit anti  –  goat secondary antibody. Blots were developed 
with the Western blot development kit from GE Healthcare. 
  TF activity assays.     Cell pellets from PBMCs or HUVECs were solubilized 
at 37  °  C for 15 min in 15 mM n-Octyl      -D-glucopyranoside (EMD Biosci-
ences). TF activity in cell lysates was measured using a one-stage clotting assay 
using human pooled plasma (American Diagnostica Inc.) (  40  ). Clotting was 
performed using a STart 4 clotting machine (Diagnostica Stago). Clotting 
times were converted to milliunits of TF activity using a standard curve estab-
lished with purifi  ed human brain TF. Protein concentrations were measured 
using a DC protein assay kit (Bio-Rad Laboratories), and TF activity was 
normalized to protein concentration. Data were expressed as fold induction 
versus control for each experiment. 
  A chromogenic assay (Actichrome TF; American Diagnostica, Inc.) was 
used to analyze TF activity. In brief, HUVECs were lysed by repeated freeze-
thaw in buff  er containing 50 mM Tris-HCl, 100 mM NaCl, 0.1% Triton 
X-100, pH 7.4. TF activity was measured in cell supernatant according to the 
manufacturer  ’  s instructions (American Diagnostica, Inc.). Cell extracts were 
mixed with human factor VII and human factor X. The reagents were incu-
bated at 37  °  C for complex formation to convert human factor X to factor Xa, 
and the amount of Xa generated was measured by its ability to cleave a chro-
mogenic substrate Spectrozyme Xa. Absorbance was read at 405 nm with a 
microplate reader (Spectra Max 340; Molecular Devices). TF concentration 
was determined by interpolation of a standard curve obtained from diff  erent 
amounts of lipidated human TF standards. For TF activity measurement in 
mouse plasma, a mixture of 10% rat plasma/90% human plasma (Sigma-
Aldrich) was added to the reaction mixture and      A405-490 was measured to 
calculate TF concentration. 
  In vivo studies.     All animal experiments were approved by the University of 
Connecticut Institutional Animal Care and Use Committee. C57/BL/6J (4  –  6 
wk old; The Jackson Laboratory) mice were fed with either vehicle (0.5% car-
boxymethyl cellulose) or celecoxib (25 mg/kg body weight) or GW501516 
(10 mg/kg body weight) by gavage for 2 d. 100      g LPS (  E. coli   serotype 
0111;B4; Sigma-Aldrich) was injected i.p. After 4  –  6 h, mice were anaesthetized 
by Avertin and whole blood was collected from caudal vena cava for TF activity 
assay, followed by isolation of murine tissues for immunohistochemistry. 
  Immunohistochemistry.     5  –  6-     m-thick frozen sections of mouse tissue 
were dried overnight at room temperature then fi  xed in acetone/ethanol (3:1 
vol/vol) for 5 min at room temperature. All steps were performed in PBS 
buff  er. Endogenous peroxidase was quenched with 3% hydrogen peroxide; 
nonspecifi  c antibody binding was blocked with a 10% normal goat serum fol-
lowed by blocking buff  er. A rat anti  –  mouse TF antibody (  41  ) (a gift from 
D. Kirchhofer, Genentech, Inc., San Francisco, CA) was biotinylated and used 
at 10      g/ml in blocking buff  er, which was applied at room temperature for 1 h. 
Primary antibodies were detected with 2.5      g/ml rabbit anti  –  rat IgG, Vecta-
stain ABC Elite (Vector Laboratories), and metal-enhanced DAB (Thermo 
Fischer Scientifi  c). Sections were counterstained with Mayer  ’  s hematoxylin. 
  Isolation of blood and plasma.     Whole blood was collected in acid-citrate 
dextrose (20 mM citric acid, 110 mM sodium citrate, and 5 mM dextrose). 
.edu/primerbank/) or designed with Primer Express software (Applied Bio-
systems) for optimal product length, GC content, and melting temperature. 
  Northern blot analysis.     Confl  uent cultures of HUVEC cells were ren-
dered quiescent for 48 h, followed by pretreatment with either vehicle, cele-
coxib, NS398, 2-AG, or GW501516 in fresh HUVEC medium for 30 min. 
10      g/ml LPS (  Escherichia coli   0111:B4; Calbiochem) was added, and cells 
were treated for an additional 3  –  6 h. Total RNA was isolated with the RNA 
STAT-60 reagent. 10      g of total RNA, quantitated spectrophotometrically, 
was electrophoresed through 1% agarose gel containing 4% (vol/vol) formal-
dehyde, and the integrity of the RNA was monitored by ethidium bro-
mide staining. RNA was transferred onto Zeta-Probe membrane (Bio-Rad 
Laboratories), and was UV cross-linked by Stratalinker (Stratagene). A 641-bp 
human TF cDNA fragment was used to detect the TF mRNA. Specifi  c 
cDNA probes were radioactively labeled by using [  32  P]-     -dCTP (GE Health-
care) by a random primer labeling system (Roche). After cross-linking, the 
membranes were prehybridized in Church-Gilbert prehybridization buff  er 
(7% SDS, 0.5 M phosphate buff  er, 0.5% BSA, 40 mM EDTA, and 20% for-
mamide) for 1 h. The membranes were hybridized with labeled probes for 
18 h and washed following the Church-Gilbert protocol (  38  ). The membranes 
were stripped in stripping buff  er (0.1  ×   SSC, 1% SDS, and 40 mM Tris-HCl, 
pH 7.6), rehybridized with diff  erent probes, and visualized by PhosphorImager 
(Molecular Dynamics). The bands were quantifi  ed using ImageQuant 
(Molecular Dynamics). The prehybridization, hybridization, and washing 
steps were all done at 65  °  C. 
  Small interfering RNA (siRNA)  –  mediated gene silencing.     Transfec-
tion of siRNA oligonucleotide duplexes to block PGIS and PGFS expres-
sion was done using Oligofectamine reagent (Invitrogen) according to the 
manufacturer  ’  s instructions. The siRNAs used were human PGIS (sense 
  AGGCCAGGAUGAAACUGACdTdT and antisense GUCAGUUUCAU-
CCUGGCCUdTdT). Oligonucleotides were synthesized by Dharmacon, 
deprotected, and duplexed. For, silencing of PGFS, SMARTpool PGF syn-
thase siRNA was obtained from Dharmacon. HUVECs were transfected with 
either 100 nM PGIS or PGFS siRNA complexed with Oligofectamine re-
agent (Invitrogen) and, 24 h after transfection, gene expression was examined 
by qRT-PCR analysis. E-cadherin (siRNA against epithelial cadherin was 
used as control). 
  Isolation of mouse lung ECs.     Lungs isolated from 21-d-old (C57/B6/129 
mixed) mice were washed several times in Hanks  ’   balanced salt solution and 
digested with 2 mg/ml collagenase A (Roche) in M199 medium, with occa-
sional mixing at 37  °  C. After treatment with 1      g/     l DNaseI, the suspension 
was passed through a cell strainer (40      m nylon; BD Biosciences) to remove 
any undigested remains. After a brief spin, the supernatant was treated with 
rat anti  –  mouse CD31 monoclonal antibody (BD Biosciences) for 20 min at 
4  °  C. The cell suspension was spun and washed twice in plain M199 me-
dium. Resuspension of the pellet in M199 medium was followed by treat-
ment with magnetic Dynabeads sheep anti  –  rat IgG (Dynal Biotech) at 4  °  C 
in a   rotator. Bead-bound cells were washed and separated from the unbound 
cells by a magnetic bar. Cells were plated in fi  bronectin-coated tissue culture 
dish in M199, 10% FBS, growth factor, and antibiotic-antimicotic agents. 
After 24 h, the cells were immortalized with a retrovirus that expresses polyoma 
middle-T-antigen (  39  ). 
  Immunofl  uorescence.     Cells grown on glass coverslips for 48 h were 
washed with PBS, fi  xed in 3.7% paraformaldehyde solution for 15 min at 
room temperature, and permeabilized with 0.2% Triton X-100 in PBS for 
5 min at room temperature. After rinsing with PBS, cells were incubated 
with a goat polyclonal anti  –  VE-cadherin antibody (1:200; Santa Cruz Bio-
technologies) for 1 h at room temperature. After washing with PBS few 
times, cells were further incubated with Alexa Fluor 488 donkey anti  –  goat 
IgG (1:1,000; Invitrogen) in 5% nonfat dry milk in PBS for 30 min at room 
temperature. After washing with PBS, cells were analyzed by a Zeiss Axio-
vert fl  uorescence microscope. 2060 COX-2/PPAR  PATHWAY REGULATES TF EXPRESSION | Ghosh et al.
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PPP was obtained as follows. In brief, the unclotted blood was centrifuged at 
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  Statistical analysis.     All data were expressed as the mean   the SEM. Statis-
tical diff  erences between two groups were analyzed using Student  ’  s   t   test un-
less specifi  ed. P   0.05 was considered signifi  cant. All experiments represent 
the mean of three or more independent experiments. For in vivo experiments, 
a signifi  cance outlier detection program using Grubb  ’  s test was performed for 
each experimental group. 
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2-AG, NE, AA, and AEA. The online version of this article is available at 
http://www.jem.org/cgi/content/full/jem.20070828/DC1. 
  We acknowledge the technical assistance of Todd Holcher. We also thank Drs. 
Daniel Kirchhofer and Wolfrum Ruf for their kind gifts of TF antibodies, Dr. James 
Morrissey for advice on TF activity measurements, and Dr. Raymond DuBois for the 
gift of PPAR constructs. 
  This work is supported by National Institutes of Health grants (HL49094, 
CA77839 to T. Hla), (DA006668 to S.K. Dey), and HL48872 to N. Mackman. 
  The authors have no confl  icting fi  nancial interests. 
Submitted:   25 April 2007 
Accepted:   10 August 2007 
  REFERENCES 
       1  .   Simmons  ,   D.L.  ,   R.M.     Botting  , and   T.     Hla  .   2004  .   Cyclooxygenase iso-
zymes: the biology of prostaglandin synthesis and inhibition.       Pharmacol. 
Rev.       56  :  387    –    437  .   
       2  .   McAdam  ,   B.F.  ,   F.     Catella-Lawson  ,   I.A.     Mardini  ,   S.     Kapoor  ,   J.A.   
  Lawson  , and   G.A.     FitzGerald  .   1999  .   Systemic biosynthesis of 
prostacyclin by cyclooxygenase (COX)-2: the human pharmacol-
ogy of a selective inhibitor of COX-2.       Proc. Natl. Acad. Sci. USA    . 
  96  :  272    –    277  .   
       3  .   Cipollone  ,   F.  ,   B.     Rocca  , and   C.     Patrono  .   2004  .   Cyclooxygenase-2 ex-
pression and inhibition in atherothrombosis.       Arterioscler. Thromb. Vasc. 
Biol.       24  :  246    –    255  .   
       4  .   Forman  ,   B.M.  ,   J.     Chen  , and   R.M.     Evans  .   1996  .   The peroxisome prolif-
erator-activated receptors: ligands and activators.       Ann. N. Y. Acad. Sci.     
  804  :  266    –    275  .   
       5  .   Gupta  ,   R.A.  ,   J.     Tan  ,   W.F.     Krause  ,   M.W.     Geraci  ,   T.M.     Willson  ,   S.K.   
  Dey  , and   R.N.     DuBois  .   2000  .   Prostacyclin-mediated activation of per-
oxisome proliferator-activated receptor delta in colorectal cancer.       Proc. 
Natl. Acad. Sci. USA    .   97  :  13275    –    13280  .   
       6  .   Lim  ,   H.  ,   R.A.     Gupta  ,   W.G.     Ma  ,   B.C.     Paria  ,   D.E.     Moller  ,   J.D.     Morrow  , 
  R.N.     DuBois  ,   J.M.     Trzaskos  , and   S.K.     Dey  .   1999  .   Cyclo-oxygenase-
2-derived prostacyclin mediates embryo implantation in the mouse via 
PPARdelta.       Genes Dev.       13  :  1561    –    1574  .   
       7  .   Gupta  ,   R.A.  ,   D.     Wang  ,   S.     Katkuri  ,   H.     Wang  ,   S.K.     Dey  , and   R.N.   
  DuBois  .   2004  .   Activation of nuclear hormone receptor peroxisome pro-
liferator-activated receptor-delta accelerates intestinal adenoma growth.   
    Nat. Med.       10  :  245    –    247  .   
       8  .   Wang  ,   D.  ,   H.     Wang  ,   Y.     Guo  ,   W.     Ning  ,   S.     Katkuri  ,   W.     Wahli  ,   B.   
  Desvergne  ,   S.K.     Dey  , and   R.N.     DuBois  .   2006  .   Crosstalk between 
peroxisome proliferator-activated receptor delta and VEGF stimulates 
  cancer progression.       Proc. Natl. Acad. Sci. USA    .   103  :  19069    –    19074  .   
       9  .   Croff  ord  ,   L.J.  ,   R.L.     Wilder  ,   A.P.     Ristimaki  ,   H.     Sano  ,   E.F.     Remmers  , 
  H.R.     Epps  , and   T.     Hla  .   1994  .   Cyclooxygenase-1 and -2 expression in 
rheumatoid synovial tissues. Eff  ects of interleukin-1 beta, phorbol ester, 
and corticosteroids.       J. Clin. Invest.       93  :  1095    –    1101  .   
        10  .   Topper  ,  J.N.  ,  J.    Cai  ,  D.    Falb  , and  M.A.    Gimbrone    Jr  .  1996  .  Identifi  cation 
of vascular endothelial genes diff  erentially responsive to fl  uid mechanical JEM VOL. 204, September 3, 2007  2061
BRIEF DEFINITIVE REPORT
release in bovine coronary arteries.       Am. J. Physiol. Heart Circ. Physiol.     
  288  :  H1344    –    H1351  .   
        31  .   Rouzer  ,   C.A.  , and   L.J.     Marnett  .   2005  .   Glycerylprostaglandin synthesis 
by resident peritoneal macrophages in response to a zymosan stimulus.   
    J. Biol. Chem.       280  :  26690    –    26700  .   
        32  .   Ho  ,   W.S.  , and   M.D.     Randall  .   2007  .   Endothelium-dependent metabo-
lism by endocannabinoid hydrolases and cyclooxygenases limits vaso-
relaxation to anandamide and 2-arachidonoylglycerol.       Br. J. Pharmacol.     
  150  :  641    –    651  .   
        33  .   Birnbaum  ,   Y.  ,   Y.     Ye  ,   Y.     Lin  ,   S.Y.     Freeberg  ,   M.H.     Huang  ,   J.R.     Perez-
Polo  , and   B.F.     Uretsky  .   2007  .   Aspirin augments 15-epi-lipoxin A4 
production by lipopolysaccharide, but blocks the pioglitazone and ator-
vastatin induction of 15-epi-lipoxin A4 in the rat heart.       Prostaglandins 
Other Lipid Mediat.       83  :  89    –    98  .   
        34  .   Solomon  ,   S.D.  ,   J.J.     McMurray  ,   M.A.     Pfeff  er  ,   J.     Wittes  ,   R.     Fowler  ,   P.   
  Finn  ,   W.F.     Anderson  ,   A.     Zauber  ,   E.     Hawk  , and   M.     Bertagnolli  .   2005  . 
  Cardiovascular risk associated with celecoxib in a clinical trial for colo-
rectal adenoma prevention.       N. Engl. J. Med.       352  :  1071    –    1080  .   
        35  .   Steff  el  ,   J.  ,   T.F.     Luscher  , and   F.C.     Tanner  .   2006  .   Tissue factor in car-
diovascular diseases: molecular mechanisms and clinical implications.   
    Circulation    .   113  :  722    –    731  .   
        36  .   Andersohn  ,   F.  ,   S.     Suissa  , and   E.     Garbe  .   2006  .   Use of fi  rst- and sec-
ond-generation cyclooxygenase-2-selective nonsteroidal antiinfl  amma-
tory drugs and risk of acute myocardial infarction.       Circulation    .   113  :
  1950    –    1957  .   
        37  .   Gislason  ,   G.H.  ,   S.     Jacobsen  ,   J.N.     Rasmussen  ,   S.     Rasmussen  ,   P.     Buch  ,   J.   
  Friberg  ,   T.K.     Schramm  ,   S.Z.     Abildstrom  ,   L.     Kober  ,   M.     Madsen  , and   C.   
  Torp-Pedersen  .   2006  .   Risk of death or reinfarction associated with the 
use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroi-
dal antiinfl  ammatory drugs after acute myocardial infarction.       Circulation    . 
  113  :  2906    –    2913  .   
        38  .   Hla  ,   T.  , and   K.     Neilson  .   1992  .   Human cyclooxygenase-2 cDNA.       Proc. 
Natl. Acad. Sci. USA    .   89  :  7384    –    7388  .   
        39  .   Paik  ,   J.H.  ,   A.     Skoura  ,   S.S.     Chae  ,   A.E.     Cowan  ,   D.K.     Han  ,   R.L.     Proia  , 
and   T.     Hla  .   2004  .   Sphingosine 1-phosphate receptor regulation of 
N-cadherin mediates vascular stabilization.       Genes Dev.       18  :  2392    –    2403  .   
        40  .   Morrissey  ,   J.H.  ,   D.S.     Fair  , and   T.S.     Edgington  .   1988  .   Monoclonal 
antibody analysis of purifi  ed and cell-associated tissue factor.       Thromb. Res.     
  52  :  247    –    261  .   
        41  .   Kirchhofer  ,   D.  ,   P.     Moran  ,   S.     Bullens  ,   F.     Peale  , and   S.     Bunting  .   2005  . 
  A monoclonal antibody that inhibits mouse tissue factor function.   
    J. Thromb. Haemost.       3  :  1098    –    1099  .                 